Although this prospective longitudinal study was the first to use Me4FDG to measure levels of SGLT2 expression in patients with type 2 diabetes taking SGLT2i treatments, the study has several limitations that should be highlighted: First, the sample size of recruited patients is small (19 patients). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.